Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease.
Atrasentan
Chronic kidney disease
Endothelin receptor antagonist
Insulin resistance
Type 2 diabetes
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
16 09 2023
16 09 2023
Historique:
received:
28
04
2023
accepted:
14
08
2023
medline:
18
9
2023
pubmed:
17
9
2023
entrez:
16
9
2023
Statut:
epublish
Résumé
Insulin resistance (IR) is a pathophysiologic hallmark of type 2 diabetes and associated with the presence of chronic kidney disease (CKD). Experimental studies suggest that endothelin-1 increases IR. We assessed the association between IR and cardio-renal outcomes and the effect of the selective endothelin receptor antagonist atrasentan on IR in patients with type 2 diabetes and CKD. We used data from the RADAR and SONAR trials that recruited participants with type 2 diabetes and CKD [eGFR 25-75 mL/min/1.73 m², urine albumin-to-creatinine ratio of 300-5000 mg/g]. IR was calculated using the homeostatic model assessment (HOMA-IR). The association between HOMA-IR and the pre-specified cardio-renal outcomes was assessed using multivariable Cox proportional hazards regression, and effects of atrasentan on HOMA-IR by a linear mixed effect model. In the SONAR trial, each log-unit increase in HOMA-IR was associated with an increased risk of the composite cardio-renal outcome [hazard ratio 1.32 (95%CI 1.09,1.60; p = 0.004)], kidney outcome [hazard ratio 1.30 (95%CI 1.00,1.68; p-value = 0.048)], and the kidney or all-cause mortality outcome [hazard ratio 1.25 (95%CI 1.01,1.55; p-value = 0.037)]. After 12 weeks treatment in the RADAR trial (N = 123), atrasentan 0.75 mg/day and 1.25 mg/day compared to placebo reduced HOMA-IR by 19.1 (95%CI -17.4, 44.3) and 26.7% (95%CI -6.4, 49.5), respectively. In the SONAR trial (N = 1914), atrasentan 0.75 mg/day compared to placebo reduced HOMA-IR by 9.6% (95%CI 0.6, 17.9). More severe IR is associated with increased risk of cardio-renal outcomes. The endothelin receptor antagonist atrasentan reduced IR. RADAR trial (Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With AtRasentan): NCT01356849. SONAR trial (The Study Of Diabetic Nephropathy With AtRasentan) NCT01858532.
Sections du résumé
BACKGROUND
Insulin resistance (IR) is a pathophysiologic hallmark of type 2 diabetes and associated with the presence of chronic kidney disease (CKD). Experimental studies suggest that endothelin-1 increases IR. We assessed the association between IR and cardio-renal outcomes and the effect of the selective endothelin receptor antagonist atrasentan on IR in patients with type 2 diabetes and CKD.
METHODS
We used data from the RADAR and SONAR trials that recruited participants with type 2 diabetes and CKD [eGFR 25-75 mL/min/1.73 m², urine albumin-to-creatinine ratio of 300-5000 mg/g]. IR was calculated using the homeostatic model assessment (HOMA-IR). The association between HOMA-IR and the pre-specified cardio-renal outcomes was assessed using multivariable Cox proportional hazards regression, and effects of atrasentan on HOMA-IR by a linear mixed effect model.
RESULTS
In the SONAR trial, each log-unit increase in HOMA-IR was associated with an increased risk of the composite cardio-renal outcome [hazard ratio 1.32 (95%CI 1.09,1.60; p = 0.004)], kidney outcome [hazard ratio 1.30 (95%CI 1.00,1.68; p-value = 0.048)], and the kidney or all-cause mortality outcome [hazard ratio 1.25 (95%CI 1.01,1.55; p-value = 0.037)]. After 12 weeks treatment in the RADAR trial (N = 123), atrasentan 0.75 mg/day and 1.25 mg/day compared to placebo reduced HOMA-IR by 19.1 (95%CI -17.4, 44.3) and 26.7% (95%CI -6.4, 49.5), respectively. In the SONAR trial (N = 1914), atrasentan 0.75 mg/day compared to placebo reduced HOMA-IR by 9.6% (95%CI 0.6, 17.9).
CONCLUSIONS
More severe IR is associated with increased risk of cardio-renal outcomes. The endothelin receptor antagonist atrasentan reduced IR.
TRIAL REGISTRATION
RADAR trial (Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With AtRasentan): NCT01356849. SONAR trial (The Study Of Diabetic Nephropathy With AtRasentan) NCT01858532.
Identifiants
pubmed: 37716952
doi: 10.1186/s12933-023-01964-8
pii: 10.1186/s12933-023-01964-8
pmc: PMC10505320
doi:
Substances chimiques
Atrasentan
V6D7VK2215
Endothelin Receptor Antagonists
0
Banques de données
ClinicalTrials.gov
['NCT01858532', 'NCT01356849']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
251Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
J Clin Endocrinol Metab. 2002 Nov;87(11):5332-5
pubmed: 12414910
Can J Physiol Pharmacol. 2022 Aug 1;100(8):828-833
pubmed: 35658576
Diabetes Care. 2022 May 1;45(5):1268-1275
pubmed: 35290429
J Am Soc Nephrol. 2014 May;25(5):1083-93
pubmed: 24722445
Diabetes Obes Metab. 2021 Feb;23(2):561-568
pubmed: 33184931
Metabolism. 1998 Dec;47(12):1468-71
pubmed: 9867075
Diabetes Obes Metab. 2018 Jun;20(6):1369-1376
pubmed: 29405626
J Clin Endocrinol Metab. 2007 Feb;92(2):379-85
pubmed: 17118997
Lancet. 2009 Jun 27;373(9682):2215-21
pubmed: 19515410
J Hum Hypertens. 2007 Sep;21(9):709-16
pubmed: 17443211
Acta Physiol Scand. 1997 Oct;161(2):211-20
pubmed: 9366964
Diabetes Care. 2013 Oct;36(10):3195-200
pubmed: 23735722
JAMA Intern Med. 2016 Dec 01;176(12):1826-1833
pubmed: 27723879
Diabetes Care. 2000 Jan;23(1):57-63
pubmed: 10857969
Diabetes. 1999 May;48(5):1120-30
pubmed: 10331419
Diabetes Care. 2007 Mar;30(3):591-6
pubmed: 17327326
Diabetes. 2006 May;55(5):1456-62
pubmed: 16644705
Diabetes Obes Metab. 2018 Aug;20(8):1829-1835
pubmed: 29604160
J Clin Endocrinol Metab. 2012 Apr;97(4):1268-76
pubmed: 22337909
Pharm Stat. 2020 May;19(3):178-186
pubmed: 31729173
J Am Soc Nephrol. 2003 Feb;14(2):469-77
pubmed: 12538749
Lancet Diabetes Endocrinol. 2018 May;6(5):361-369
pubmed: 29503172
Br J Clin Pharmacol. 2013 Oct;76(4):573-9
pubmed: 23228194
Lancet. 2019 May 11;393(10184):1937-1947
pubmed: 30995972
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Diabetes. 1996 Mar;45(3):316-21
pubmed: 8593936